North Texas cat owners among those defrauded in multimillion-dollar scheme involving smuggled drugs
DALLAS - A Texas woman received probation and had to give up more than $4 million in cash and property connected to a scam targeting cat owners.
The woman, who is not a licensed vet, misdiagnosed sick cats and prescribed unauthorized medicine.
Nicole Randall seized the opportunity to help the sick cats but also help her own pocketbook, too.
According to court documents, between February 2020 and May 2022, Randall used fake names to smuggle unapproved cat medication into the U.S. disguised as facial masks, pet shampoo, beauty products and cosmetics.
Local perspective
When Benrbook-native Nat Burton's cat was diagnosed with a fatal disease called feline infectious peritonitis (FIP), there was no treatment.
"We kept him comfortable until he couldn't go anymore," she said. "After that, I said, 'I'm not going to let this happen again. I'm going to do everything I can.'"
And when her seven-week-old kitten tested positive for the disease, Burton stayed true to her word.
Veterinarians, at the time, couldn't prescribe the life-saving medication. So people like Burton had to turn online.
That's how she found the FIP Warriors Facebook group run by a woman named Nicole Randall from Cedar Park, Texas, just north of Austin.
Burton shared all the information about her kitten brisket's diagnosis, ordered the medication and paid Randall through Zelle.
"I never had a problem getting the meds and [my cat] improved in like three days," she recalled.
Unbeknownst to her, the FDA was onto Randall and started an undercover investigation. They discovered she was smuggling the medication from China and charging enormous prices to customers, making millions of dollars.
Libby Cooley, from Dallas, also purchased medication through Randall.
"I actually remember years ago, kind of my reaction was a little bit of shock because we had become aware that she was spending, kind of flamboyantly spending money," she recalled.
In one year, Cooley spent around $10,000.
"It kind of makes you think, 'If she has this much money, how much did that medication actually cost?' Right?"
Randall pleaded guilty to a federal charge of introducing an adulterated drug into interstate commerce.
Randall's scheme was highly profitable.
As part of the plea agreement, Randall agreed to forfeit four real properties, ten financial accounts, and a Tesla, worth roughly $4 million combined and traceable to her proceeds from smuggling and distributing the unapproved drugs.
"It really just makes me indescribably angry," said Burton.
Big picture view
These days, licensed veterinarians can prescribe the drugs, and pharmacies can make it.
Cooley now works for Las Colinas Compound and Wellness Pharmacy. They are able to get the medication into the hands of pet owners in less than 24 hours.
"It's important for veterinarians to understand the disease, to learn about it now that they're able to treat it and to be able to write prescriptions and care for their patients the way that they want to," advised Cooley.
What's next
Randall was sentenced to one year probation.
Burton said she is using a prescription medication to treat one of her cats, and it is working.
Cooley says the Las Colinas pharmacy hopes to work with pharmacies across the country to get the formulas in their hands and the drug available in all 50 states.
The Source
Information in this article comes from U.S. District of Oregon court documents, criminal complaints and interviews with North Texas cat owners targeted in the scheme.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those therapies weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.'
Yahoo
29 minutes ago
- Yahoo
A girlfriend of a New Orleans inmate still at large is charged with aiding his escape
Agents with the Louisiana Bureau of Investigation and US Marshals arrested a former correctional center employee Monday who is accused of helping one of the two New Orleans prison escapees still on the run plan the brazen escape. Darriana Burton was taken into custody without incident in New Orleans and is facing a felony charge of conspiracy to commit simple escape related to her alleged involvement in facilitating Derrick Groves' escape last month, the state's attorney general said in a statement. 'Burton is believed to be the current girlfriend of Derrick Groves. We have confirmed they were in an on-again, off-again relationship for three years,' Liz Murrill said. Burton worked for the Orleans Parish Sheriff's Office from August 2022 to March 2023, according to Murrill. She does not have a defense attorney listed yet, according Orleans Parish Magistrate Court records, and joins more than a dozen other people already charged with helping the 10 escapees, both before and after they broke out. Special agents with the Louisiana Bureau of Investigation discovered there was 'probable cause' that Burton 'knowingly and willfully' helped plan the escape, which saw inmates removing a sink-toilet combination unit from a cell, use a tool to saw through steel bars behind the fixture, and leave the Orleans Parish Correctional Center after midnight on May 16. During their review, investigators discovered Burton had exchanged text messages and video calls with Groves in the days leading up to the escape. 'As part of the investigation, agents reviewed inmate communications transmitted through SmartCom, an internet-based messaging and video call system utilized by inmates via facility-issued iPADs,' the Louisiana Bureau of Investigation wrote in an arrest warrant affidavit for Burton. 'This conversation remained intentionally vague,' the affidavit said, and appeared to coordinate communication on unmonitored lines to plan the escape. 'It was implied that Burton would initiate a separate, unmonitored phone call' immediately after the SmartCom session ended, according to the affidavit, which alleged that her actions demonstrated 'intentional and active involvement in the planning phase of the escape.' Eight of the escapees have been caught – most of them in New Orleans. Only Groves, 27, convicted last October of killing two people, and Antoine Massey, 32, who has a history of escaping custody, have continued to evade law enforcement. There is now a $50,000 reward for information that leads to either of their arrests, as multiple law enforcement agencies are asking the public to remain vigilant and continue to be on the lookout for the two men. Tips from the public continue to trickle in, the US Marshals Service says. 'The joint investigation between multiple law enforcement agencies continues and we continue to follow up on Crimestoppers GNO tips and develop new leads,' Deputy US Marshal Brian Fair told CNN. 'To those that would aid or hide Groves and or Massey, you are doing a disservice to the community and you may have your own day in court with felony charges in the near future,' Fair said. Last week, law enforcement agencies searched the home where they believe Massey may have recorded a video proclaiming his innocence and asking rapper Lil Wayne and President Donald Trump for help, but since then, the manhunt has gone quiet. 'We will continue to pursue anyone and everyone who has aided and abetted these criminals. We will find you, arrest you, and prosecute you to the full extent of the law,' Murrill said in the statement.


Boston Globe
an hour ago
- Boston Globe
FDA looks to AI to enhance efficiency
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The agency plays a central role in pursuing the agenda of the US health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Advertisement Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that AI is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. Advertisement 'I don't want to be dismissive of speeding reviews at the FDA,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' A major AI rollout closely follows the release of a report by Kennedy's MAHA Commission, which uses an acronym for Make America Healthy Again, that was found to be rife with references to scientific research apparently fabricated by an AI program. For some cases, the FDA officials proposed speeding major drug approvals by requiring only one major study in patients rather than two, a practice the agency has used in recent years. The pandemic provided a precedent, they said, for accelerating the process. 'We believe this is clear demonstration that rapid or instant reviews are possible,' Makary and Prasad wrote. But Holland pointed out that during the pandemic, many staff members were transferred from routine duties, including overseas inspections of food or drug facilities, and reassigned to hasten critical COVID product reviews. The agency was also better staffed. In recent months, the FDA shed about 1,940 employees, reducing the workforce to 8,000 from roughly 10,000. Last week, the agency introduced Elsa, an AI large-language model similar to ChatGPT. The FDA said it could be used to prioritize which food or drug facilities to inspect, to describe side effects in drug safety summaries and to perform other basic product-review tasks. The FDA officials wrote that AI held the promise to 'radically increase efficiency' in examining as many as 500,000 pages submitted for approval decisions. Advertisement Current and former health officials said the AI tool was helpful but far from transformative. For one, the model limits the number of characters that can be reviewed, meaning it is unable to do some rote data analysis tasks. Its results must be checked carefully, so far saving little time. Staff members said the model was hallucinating, or producing false information. Employees can ask the Elsa model to summarize text or act as an expert in a particular field of medicine. Makary said the AI models were not being trained by data submitted by the drug or medical device industry. When it comes to food oversight, Makary and Prasad said there would be a renewed focus on 'our increasingly chemically manipulated diet,' a goal embraced by Republicans and Democrats. 'For all additives,' the article said, 'the benefit-to-harm balance must be reevaluated.' Although the Trump administration is seeking steep cuts in the FDA's budget for the next fiscal year, the food division is expected to receive additional funds. Others noted the fine line agency officials were walking, given Kennedy's complaints that the FDA is too close to the drug industry and the Trump administration's business-friendly approach. Makary and Prasad wrote that the FDA must be 'partners with industry' while avoiding 'a cozy relationship that has characterized the agency in the past.' Dr. Reshma Ramachandran, a director of the Yale Collaboration for Regulatory Rigor, Integrity and Transparency, pointed out that Makary and Prasad were going on a six-city, closed-door listening tour to meet with chief executives of the drug industry. 'How is this guarding the agency 'against a cozy relationship' with industry?' she asked. The FDA priorities 'read as though they're straight out of PhRMA's playbook,' she said, referring to the trade group. Advertisement This article originally appeared in